APPLY TREATMENT TO CLINICAL SYNDROMES
Antifungal Pharmacology Essentials
Antifungal selection depends on the organism, infection site, disease extent, and host immune function. A localized superficial infection may respond to topical treatment, while scalp, nail, extensive mucosal, or invasive disease may require systemic therapy.
Confirm the diagnosis when the appearance is atypical, treatment has failed, or prolonged systemic therapy is being considered (Ballou & Miller, 2026).
Connect Mechanism to Clinical Use
Azoles interfere with ergosterol synthesis in fungal cell membranes. Topical agents treat selected superficial infections; systemic azoles have different spectra, absorption requirements, and interaction profiles.
Terbinafine inhibits squalene epoxidase and is particularly useful against dermatophytes.
Polyenes bind ergosterol and disrupt fungal membranes. Nystatin is used for selected local candidal infections. Amphotericin formulations are used for serious systemic infections and require substantial toxicity monitoring.
Echinocandins inhibit fungal cell-wall beta-glucan synthesis and are used intravenously for selected invasive infections. They do not serve as routine outpatient treatment for uncomplicated tinea (Ballou & Miller, 2026; Rybak, 2026).
Dermatophyte Skin Infection
Localized tinea corporis, cruris, or pedis often responds to a topical antifungal. Clotrimazole 1% applied twice daily for an appropriate site-specific course is one common option.
Apply treatment to the involved skin and a small surrounding margin. Duration varies with the site and product; premature discontinuation can contribute to persistence.
Tinea capitis requires systemic therapy because topical treatment does not adequately reach the infected hair shaft. Extensive disease, immune compromise, or failure of appropriate topical therapy also changes the treatment approach (Ballou & Miller, 2026).
Nail Infection
Confirm fungal infection before exposing a patient to a prolonged oral regimen. Trauma, psoriasis, and other nail disorders can resemble onychomycosis.
For an appropriate adult, oral terbinafine 250 mg daily is commonly used for six weeks for fingernails or twelve weeks for toenails. Assess liver disease and obtain baseline liver testing. Review interactions and counsel about hepatic symptoms, taste or smell disturbances, and other significant adverse effects.
Visible nail recovery lags behind microbiologic treatment because healthy nail must grow out (Ballou & Miller, 2026).
Vulvovaginal Candidiasis
Symptoms are not specific enough to establish candidiasis in every patient. Evaluate recurrent, atypical, or persistent symptoms rather than repeatedly prescribing empiric treatment.
Uncomplicated disease in a nonpregnant patient may be treated with a recommended topical azole regimen or fluconazole 150 mg orally once.
During pregnancy, use a topical azole for seven days. Oral fluconazole should not be substituted for this pregnancy regimen.
Recurrent disease, severe symptoms, immune compromise, or non-albicans Candida may require testing and a longer or different approach (Ballou & Miller, 2026).
Oral and Esophageal Candidiasis
Mild oropharyngeal candidiasis may respond to topical treatment. Correct contributors such as denture hygiene problems or failure to rinse after inhaled corticosteroid use.
Dysphagia or odynophagia raises concern for esophageal involvement, which requires systemic treatment and assessment of the underlying host condition.
Recurrent oral candidiasis should prompt review of medications, diabetes, immune function, and other contributing factors (Ballou & Miller, 2026).
Monitor Systemic Treatment
Systemic azoles can cause hepatic toxicity and clinically important interactions. Some also affect QT intervals. Review anticoagulants, statins, antiarrhythmics, antiretrovirals, and immunosuppressants before prescribing.
Suspected invasive fungal infection requires prompt assessment of immune status, likely organism, diagnostic testing, and specialist treatment. Fluconazole does not provide universal coverage for invasive fungi (Rybak, 2026).
Related YourDNP Resources
Content last reviewed:
References
Infectious Diseases Society of America. (2016). Clinical practice guideline for the management of candidiasis: 2016 update. https://www.idsociety.org/practice-guideline/candidiasis/
Ballou, J. M., & Miller, L. E. (2026). Superficial fungal infections. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed.). McGraw Hill.
Rybak, J. M. (2026). Invasive fungal infections. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed.). McGraw Hill.